Anistreplase: An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents.Thrombolytic Therapy: Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts.Streptokinase: Streptococcal fibrinolysin . An enzyme produced by hemolytic streptococci. It hydrolyzes amide linkages and serves as an activator of plasminogen. It is used in thrombolytic therapy and is used also in mixtures with streptodornase (STREPTODORNASE AND STREPTOKINASE). EC 3.4.-.Controlled Clinical Trials as Topic: Works about clinical trials involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicines, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trials are characterized as RANDOMIZED CONTROLLED TRIALS AS TOPIC.Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).Fibrinolytic Agents: Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.

Thrombolytic therapy in Europe: current status. (1/39)

Thrombolytic therapy is a practical, effective approach to the management of acute myocardial infarction that is widely used in Europe today. Early European trials demonstrated a clear reduction in mortality in patients who received thrombolytic therapy compared with those given conventional treatment. The findings of experimental studies suggest that early reperfusion of the infarct-related artery reduces myocardial damage, which results in the preservation of left ventricular function and, in turn, may improve survival. Although tissue plasminogen activator (t-PA) has been shown to produce more rapid and complete reperfusion than streptokinase, two large-scale clinical trials in which t-PA was given as a standard 3- or 4-h infusion provided no evidence of a survival advantage with this agent. However, the accelerated t-PA regimen used in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) study was associated with a lower mortality than streptokinase or a combination of t-PA and streptokinase, thus lending support to the 'open artery' theory. Two recent studies conducted in Europe, the Grampian Region Early Anistreplase Trial (GREAT) and the European Myocardial Infarction Project (EMIP), have demonstrated the feasibility, safety, and efficacy of early thrombolytic therapy before admission to hospital. In GREAT, anistreplase (APSAC) was administered at home by general practitioners. In EMIP, this same agent was given by emergency medical personnel. In both studies, pre-hospital administration reduced the time between the onset of symptoms and initiation of thrombolysis and was associated with a lower mortality rate. Recent data from the European Cooperative Group Study show that the benefits of thrombolytic therapy are maintained for up to 5 years. Research continues in an effort to develop safer and more effective thrombolytic agents. Educational efforts to familiarize the public with the symptoms of myocardial infarction and the development of more rapid, efficient emergency response systems may also improve the outcome of thrombolytic therapy by shortening the time between symptom onset and thrombolytic drug administration.  (+info)

Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG. (2/39)

OBJECTIVE: To examine the induction of antistreptokinase antibodies after giving streptokinase or anistreplase to patients with acute myocardial infarction. DESIGN: Patients were randomly allocated to receive either 1.5 x 10(6) IU, streptokinase or 30U anistreplase in a double blind study. Blood samples were collected immediately before treatment and subsequently at intervals up to 30 months; plasma samples were assayed for streptokinase resistance titre (functional assay) and streptokinase binding by IgG (microradioimmunoassay). SETTING: Cardiology department in a general hospital. PATIENTS: 128 consecutive eligible patients. Samples were collected for up to one year according to a prospective design: a subsection of 47 patients was selected for intensive study over the first 14 days. After one year, all available patients (67) were sampled on one further occasion. RESULTS: Antibody responses to streptokinase and anistreplase were similar. Streptokinase resistance titres exceeded pretreatment concentrations five days after dosing, and values peaked at 14 days. By 12 months after dosing, 92% of resistance titres (n = 84) had returned to within the pretreatment range. Antistreptokinase IgG concentrations also exceeded baseline concentrations within five days and peaked at 14 days. Half of the individual values had returned to within the pretreatment range by 12 months (n = 84) and 89% by 30 months (n = 18). CONCLUSION: Although we cannot be sure of the clinical significance, because of the increased likelihood of resistance due to antistreptokinase antibody, streptokinase and anistreplase may not be effective if administered more than five days after an earlier dose of streptokinase or anistreplase, particularly between five days and 12 months, and increased antistreptokinase antibody may increase the risk of allergic-type reactions.  (+info)

Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group. (3/39)

OBJECTIVE: To assess the feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners. DESIGN: Randomised double blind parallel group trial of anistreplase 30 units intravenously and placebo given either at home or in hospital. SETTING: 29 rural practices in Grampian admitting patients to teaching hospitals in Aberdeen (average distance 36 (range 16-62) miles). PATIENTS: 311 patients with suspected acute myocardial infarction and no contraindications to thrombolytic therapy seen at home within four hours of onset of symptoms. MAIN OUTCOME MEASURES: Time saving, adverse events, Q wave infarction, left ventricular function. RESULTS: Anistreplase was administered at home 101 minutes after onset of symptoms, while anistreplase was given in hospital 240 minutes after onset of symptoms (median times). Adverse events after thrombolysis were infrequent and, apart from cardiac arrest, not a serious problem when they occurred in the community: seven of 13 patients were resuscitated after cardiac arrest out of hospital. By three months after trial entry the relative reduction of deaths from all causes in patients given thrombolytic therapy at home was 49% (13/163 (8.0%) v 23/148 (15.5%); difference -7.6% (95% confidence interval -14.7% to -0.4%), p = 0.04). Full thickness Q wave infarction was less common in patients with confirmed infarction receiving treatment at home (65/122 (53.3%) v 76/112 (67.9%); difference -14.6% (95% confidence interval -27.0% to -2.2%), p = 0.02). CONCLUSIONS: General practitioners provided rapid pre-hospital coronary care of a high standard. Compared with later administration in hospital, giving anistreplase at home resulted in reduction in mortality, fewer cardiac arrests, fewer Q wave infarcts, and better left ventricular function. Benefits were most marked where thrombolytic therapy was administered within two hours of the onset of symptoms.  (+info)

Oesophageal dissection after thrombolytic treatment for myocardial infarction. (4/39)

A 62 year old woman admitted with a history suggesting acute myocardial infarction had thrombolytic treatment with anisoylated plasminogen-streptokinase activator complex, which resulted in submucosal haemorrhage in the oesophagus; this caused dissection of the wall of the oesophagus and complete dysphagia. The haematoma resolved spontaneously, leaving behind a diverticulum, with reduced peristalsis and delayed emptying but no obstruction.  (+info)

The pharmacological modulation of thrombin-induced cerebral thromboembolism in the rabbit. (5/39)

1. Intracarotid (i.c.) administration of thrombin induced a marked accumulation of 111indium-labelled platelets and 125I-labelled fibrinogen within the cranial vasculature of anaesthetized rabbits. 2. Thrombin (100 iu kg-1, i.c.) - induced platelet accumulation was completely abolished by pretreatment with desulphatohirudin (CGP 39393; 1 mg kg-1 i.c., 1 min prior to thrombin). Administration of CGP 39393 1 or 20 min after thrombin produced a significant reduction in platelet accumulation. 3. Intravenous (i.v.) administration of the platelet activating factor (PAF) receptor antagonist BN 52021 (10 mg kg-1) 5 min prior to thrombin (100 iu kg-1, i.c.) had no effect on platelet accumulation. 4. An inhibitor of NO biosynthesis, L-NG-nitro arginine methyl ester (L-NAME; 100 mg kg-1, i.c.), had no significant effect on the cranial platelet accumulation response to thrombin (10 iu kg-1, i.c.) when administered 5 min prior to thrombin. 5. Defibrotide (32 or 64 mg kg-1 bolus i.c. followed by 32 or 64 mg kg-1 h-1, i.c., infusion for 45 min) treatment begun 20 min after thrombin (100 iu kg-1, i.c.) did not significantly modify the cranial platelet accumulation response. 6. Cranial platelet accumulation induced by thrombin (100 iu kg-1, i.c.) was significantly reversed by the fibrinolytic drugs urokinase (20 iu kg-1, i.c., infusion for 45 min), anisoylated plasminogen streptokinase activator complex (APSAC) (200 micrograms kg-1, i.v. bolus) or recombinant tissue plasminogen activator (rt-PA; 100 micrograms kg-1, i.c. bolus followed by 20 micrograms kg-1 min-1, i.c., infusion for 45 min) administered 20 min after thrombin.8. These results suggest that neither endogenous PAF nor NO modulate thrombin-induced intracranial platelet accumulation in the rabbit. However, fibrin deposition appears to play an important role as shown by the ability of fibrinolytic agents to reverse platelet and fibrinogen accumulation induced by i.c. thrombin.  (+info)

Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis. (6/39)

PURPOSE: Over the past 2 decades the use of thrombolytic therapy in the management of peripheral occlusive diseases, most notably peripheral arterial occlusion (PAO) and deep venous thrombosis (DVT), has become an accepted and potentially preferable alternative to surgery. We examined the period when urokinase was in short supply and subsequently unavailable, to explore potential differences in clinical outcome and economic effect between urokinase and recombinant tissue plasminogen activator (rt-PA). MATERIAL AND METHODS: Data were obtained from the Premier Perspective Database, a broad clinical database that contains information on inpatient medical practices and resource use. The study population included all patients hospitalized in 1999 and 2000 with a primary or secondary diagnosis of PAO or DVT. Incidence was calculated for common adverse events, including bleeding complications, intracranial hemorrhage, amputation, and death. Cost data were also abstracted from the database, and are expressed as mean +/- SD. RESULTS: Demographic variables were similar in the urokinase and rt-PA groups. The rate of bleeding complications was similar in the urokinase and rt-PA groups. There were no intracranial hemorrhages in the urokinase group, compared with a rate of 1.5% in the rt-PA PAO group (P = .087) and 1.9% in the rt-PA DVT group (P = .175). The in-hospital mortality rate was lower in the urokinase-treated PAO subgroup (3.6% vs 8.5%; P = .026), but a similar finding in the DVT subgroup did not achieve statistical significance (4% vs 9.8%; P = .069). While pharmacy costs were greater in the urokinase-treated group (US 5472 dollars +/- US 5579 dollars vs US 3644 dollars +/- US 6009 dollars, P < .001; PAO subgroup, US 11,070 dollars +/- US 15,409 dollars vs US 6150 dollars +/- US 12,398 dollars, P = .003), overall hospital costs did not differ significantly between the 2 groups. This finding appears to be explained by a shorter hospital stay and reduced room and board costs in the urokinase-treated group. CONCLUSION: There were significant differences in outcome in patients with PAO and DVT who received treatment with urokinase and rt-PA. While pharmacy costs were significantly greater when urokinase was used, reduction in length of stay accounted for similar total hospital costs compared with rt-PA. These findings must be considered in the context of the retrospective nature of the analysis and the potential to use dosing regimens that differ from those in this study.  (+info)

Serum myoglobin and creatine kinase enzymes in acute myocardial infarction treated with Anistreplase. (7/39)

AIMS: To compare plasma myoglobin concentration and cardiac enzyme activity with electrocardiographic (ECG) changes in two groups of patients (reperfused and non-reperfused) participating in a placebo-controlled randomised double blind trial of treatment of myocardial infarction (MI) with intravenous thrombolytic therapy (Anistreplase). METHODS: Twenty two patients with confirmed MI obeying strict inclusion and exclusion criteria were studied. Plasma myoglobin was measured by radioimmunoassay and creatine kinase enzyme (CK and CKMB) by NAC activated and NAC activated/immunoinhibition methods respectively in all patients before and at frequent intervals after injection of Anistreplase or placebo. Patients were divided into reperfused (R) and non-reperfused (NR) groups on the basis of ECG criteria. Reperfusion was diagnosed if the measured ST segment elevation fell by greater than or equal to 50% at 2 hours post dosing. RESULTS: The time to peak (TTP) myoglobin was significantly less in the R group compared with the NR group but there was considerable overlap in the range of values. The area under the enzyme time curves (AUCs) and summed ST segment epsilon ST elevations were significantly smaller in the R compared with the NR group. CONCLUSIONS: Although TTP myoglobin results were significantly lower in the R group, TTP myoglobin will probably not be useful as an non-invasive indicator of reperfusion because of the overlap in values between the two groups. The significant reduction in the AUC and epsilon ST only in the R group suggests decreased infarct size. However, in this small preliminary study reperfusion did not occur more frequently with Anistreplase than without.  (+info)

Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. (8/39)

The thrombolytic and systemic effects of BM 06.022 were evaluated and compared with those of alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. BM 06.022 consists of the kringle-2 and protease domains of human tissue plasminogen activator (t-PA) and is unglycosylated because of its expression in Escherichia coli cells. Thrombus formation in anesthetized open chest dogs was induced by electrical injury to the intimal surface of the left circumflex coronary artery at a high level site of obstruction. In heparinized dogs, none of six vehicle-treated animals exhibited reperfusion. Reperfusion was achieved in four of six dogs at 18.3 +/- 6 min after intravenous bolus injection of 140 kU/kg (0.24 mg/kg) of BM 06.022, whereas four of six dogs exhibited reperfusion later (p less than 0.05) at 76.5 +/- 16.1 min during infusion of 1.33 mg/kg of alteplase (0.13 mg/kg as initial bolus injection, followed by 0.66 mg/kg over 1 h and 0.53 mg/kg over 2 h). Significantly later (p less than 0.05) reperfusion than that achieved with BM 06.022 was achieved in five of six dogs at 57.8 +/- 12.1 min after intravenous injection of 0.4 U/kg of anistreplase. Streptokinase (21,000 IU/kg over 60 min) and urokinase (20,000 IU/kg as an intravenous bolus injection, followed by 20,000 IU/kg over 89 min) each induced reperfusion in three of six dogs but at 67 +/- 12 and 84.3 +/- 17.1 min (p less than 0.05 vs. BM 06.022), respectively.(ABSTRACT TRUNCATED AT 250 WORDS)  (+info)

*Anistreplase

... is a thrombolytic drug. Anistreplase has been developed by Beecham as Eminase. It is also known as anisoylated ... Grampion Region Early Anistreplase Trial (GREAT)". J Epidemiol Community Health. 47 (5): 377-381. doi:10.1136/jech.47.5.377. ... "Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners". Br J Gen Pract. 45 ... new evidence from Grampian region early anistreplase trial (GREAT)". BMJ. 312 (7025): 212-5. doi:10.1136/bmj.312.7025.212. PMC ...

*APSAC

... anistreplase). ...

*List of MeSH codes (D12.776.124)

... anistreplase MeSH D12.776.124.125.662.537.900 -- streptodornase and streptokinase MeSH D12.776.124.125.662.768 -- tissue ...

*List of drugs: An-Ap

... anistreplase (INN) anitrazafen (INN) anivamersen (USAN, INN) Anodynos-DHC Anolor 300 Anoquan anpirtoline (INN) anrukinzumab ( ...

*Beecham Group

... anistreplase) Engerix-B (hepatitis B vaccine) Floxapen (flucloxacillin) granisetron Havrix (hepatitis A vaccine) Orbenin ( ...

*List of MeSH codes (D08)

... anistreplase MeSH D08.811.277.656.300.760.640 --- proprotein convertase 1 MeSH D08.811.277.656.300.760.646 --- proprotein ... anistreplase MeSH D08.811.277.656.300.775.900 --- streptodornase and streptokinase MeSH D08.811.277.656.350 --- exopeptidases ...

*Thrombolysis

Some fibrinolytics are: Streptokinase (Kabikinase) Urokinase Anistreplase (Eminase) Recombinant tissue plasminogen activators ( ...

*International Studies of Infarct Survival

... and anistreplase to each other, and also compared the anticoagulant heparin to no heparin. All patients were also given aspirin ... a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin ...

*ATC code B01

... combinations with proton pump inhibitors B01AD01 Streptokinase B01AD02 Alteplase B01AD03 Anistreplase B01AD04 Urokinase B01AD05 ...
Thrombolytic therapy has been shown to improve clinical outcome when administered early after the onset of symptoms of acute myocardial infarction; the mechanism of benefit is believed to be reestablishment and maintenance of coronary artery patency.
One measure of the success of thrombolysis is the early patency status of the infarct-related coronary artery. The Thrombolysis in Myocardial Infarction (TIMI) study group designated patency grades 0 (occluded) or 1 (minimal perfusion) as thrombolysis failure and grade 2 (partial perfusion) or 3 (complete perfusion) as success. To evaluate their true functional significance, perfusion grades were compared with enzymatic and electrocardiographic (ECG) indexes of myocardial infarction in 359 patients treated within 4 h with anistreplase (APSAC) or streptokinase. Serum enzymes and ECGs were assessed serially. Patency was determined at 90 to 240 min (median 2.1 h) and graded by an observer who had no knowledge of patient data.. Results for the two drug arms were similar and combined. Distribution of patency was grade 0 = 20%, n = 72; grade 1 = 8%, n = 27; grade 2 = 16%, n = 58 and grade 3 = 56%, n = 202. Interventions were performed after angiography but within 24 h in 51% (n = 37), 70% (n = 19), ...
The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction. The DDD of urokinase is based on treatment of acute lung emboli. The DDDs are either expressed in international units or gram ...
40 903 patients (median age 62 y) who presented to the hospital within 6 hours of symptom onset, had chest pain lasting ≥ 20 minutes, and showed signs of ≥ 0.1 mV of ST-segment elevation in ≥ 2 leads on electrocardiography. Exclusion criteria were active bleeding, recent trauma or major surgery, history of stroke, noncompressible vascular punctures, or previous treatment with streptokinase (SK) or anistreplase ...
An initiative of Alzheimers Australia, this website is a practical and comprehensive resource to help people to plan ahead for their future. It gives the information needed to make decisions and helps to put decisions into action. Resources include worksheets to help people step through the processes involved in planning ahead. It also has information and up to date links for all States and Territories as well as information available in 30 languages.. ...
All trials randomized patients to fibrinoltyic therapy or control. Treatment for each trial was as follows: GISSI-1: streptokinase (SK), 1.5 MU vs open control ISAM: SK, 1.5 MU vs placebo; single IV bolus aspirin; IV heparin, 5000 U + 800-1000 U/h for 72-96 h AIMS: APSAC, 30 U vs placebo; IV heparin at 6 h, 1000-1500 U/h ISIS-2: SK, 1.5 MU vs placebo; aspirin ASSET: tPA, 100 mg vs placebo; IV heparin, 5000 U + 1000 U/h for 24 h USIM: urokinase, 1 MU x 2 bolus vs open control; IV heparin, 10000 U + 1000 U/h for 48 h ISIS-3: SK, 1.5 MU or tPA, 0.6 MU/kg or APSAC, 30 U vs open control; aspirin; SC heparin, 12500 U bd for 7 days EMERAS: SK, 1.5 MU vs placebo; aspirin LATE: tPA, 100 mg vs placebo; aspirin; IV heparin, 5000 U + 1000 U/h for 48 h. ...
Westhill Academy, Grampian Region: A Report by HM Inspectors of Schools by Great Britain, 9780748048748, available at Book Depository with free delivery worldwide.
There is a need for a simple clinical measurement that will indicate the extent of myocardial salvage after successful thrombolysis. This study examined whether coronary artery reperfusion reduced the infarct size as assessed electrocardiographically after thrombolytic treatment. The sum of the (sigma) ST segment area in leads showing ST segment elevation in the 12 lead electrocardiogram at presentation was used as an index of potential myocardial injury (initial ischaemic index). The evolved infarct size at 48 h was assessed by a QRS scoring system. Two groups of patients, both admitted with anterior myocardial infarction within 6 h of onset, were studied. Group 1 (n = 35) received analgesia only and group 2 (n = 33) received thrombolytic treatment either by the intracoronary (streptokinase, n = 13) or intravenous route (anistreplase, n = 20). Reperfusion was assessed angiographically. The mean (SD) potential infarct size assessed by the initial ischaemic index was similar in both groups (group ...
Grampians Tourism: TripAdvisor has 27,600 reviews of Grampians Hotels, Attractions, and Restaurants making it your best Grampians resource.
This half day workshop will deliver an interactive workshop for PCAs working in community and aged care. The workshop is designed to enhance your skills and develop a better understanding about Symptom Management and a Palliative Approach for older people living in residential aged care or the community.. ...
Victoria, West Victoria, Grampians. Located 260 kms west of Melbourne, the Grampians have a lot to offer the traveller. Spectacular rock formations, mountains and scenery make it a popular getaway. For the 4wder, there are numerous 4wd tracks to explore.
Eventbrite - ACK presents PAMIS Family Fun Day - Grampian - Saturday, 15 July 2017 at Aberdeen Sports Village - Sports Centre, Aberdeen, Scotland. Find event and ticket information.
Professor Lovell held high positions in the American Society for Testing and Materials (ASTM), the American Society of Civil Engineers (ASCE), the Transportation Research Board, and other professional organizations, from which he received numerous awards. He was a Fellow of both the ASTM and the ASCE. He was a past district governor of Lions International, a past president of the Lafayette Lions Club, a member of the Board of Directors of the Lafayette Rotary Club, a past president of the Greater Lafayette Civic Theatre, a charter member of the Covenant Presbyterian Church, West Lafayette, and an elder of the Central Presbyterian Church, Lafayette ...
Shop Proteasome activator complex ELISA Kit, Recombinant Protein and Proteasome activator complex Antibody at MyBioSource. Custom ELISA Kit, Recombinant Protein and Antibody are available.
Every effort has been made to acknowledge the original authors of any external images used. But on the most part images and content in this blog are copyrighted to Margaret Lawson (c) 2013. All rights reserved ...
Common areas. As is expected of such a long-established, community based facility you will feel as though you are entering a calm and welcoming home-like environment. Residents are provided with large, open lounge areas, comfortably furnished with individual recliner chairs and couches, and large TV (LCD) screens for ease of viewing, or may escape into quieter sitting rooms. Fresh, daily-made meals are served in the large open dining areas or alternatively there is access to a private dining room for residents and family, designed to make you feel relaxed and at home.. Sweeping gardens with uninterrupted views to the Grampians provide space to stroll and relax within private and secure outdoor areas that incorporate courtyards, established trees, manicured gardens and raised garden beds, and peaceful retreats maintained by community volunteers. All of this and yet only a short walk into the centre of town, where an array of shops and local businesses boast services for your convenience.. In ...
In the Grampian (Ordovician) orogenic belt in northwestern Ireland the Dalradian Supergroup abuts and interleaves with an enigmatic psammite-dominant unit, with relict latest Precambrian granulite-facies assemblages, known as the Slishwood Division. These two units were most likely tectonically juxtaposed during the D3 phase of Dalradian deformation. Using Ar-Ar, Rb-Sr and Sm-Nd methods, 53 new mineral ages have been obtained from both rock units, and from pegmatites intruding them, in an attempt to constrain the timing of their juxtaposition and the history they subsequently shared. Prior to D3 (c. 480 Ma), retrograde hornblende poikiloblasts grew in granulite-facies metabasite pods within the Slishwood Division. Tectonic juxtaposition (D3) with the Dalradian is loosely constrained between 479 Ma and 459 Ma but is likely to have occurred between 470 Ma and 459 Ma. Dalradian peak metamorphic conditions were attained shortly after D3, at around 460 Ma. Extensional collapse of the orogen, with ...
Purdue University, 610 Purdue Mall, West Lafayette, IN 47907, (765) 494-4600. © 2015 Purdue University , An equal access/equal opportunity university , Copyright Complaints , Maintained by Office of XYZ. Trouble with this page? Disability-related accessibility issue? Please contact Office of XYZ at [email protected] ...
Attribution: © Aberdeenshire Archaeological Service. You may: copy, display, store and make derivative works [eg documents] solely for licensed personal use at home or solely for licensed educational institution use by staff and students on a secure intranet.. Under these conditions: Display Attribution, No Commercial Use or Sale, No Public Distribution [eg by hand, email, web]. Full Terms & Conditions and Licence details. ...
All data on NatureShare is licensed under a Creative Commons Attribution 2.5 Australia License . Free: NatureShare is, and will always be, a free and open service. Warranty: NatureShare services and all software are provided on an as is basis without warranties of any kind, either express or implied, including, without limitation, fitness for a particular purpose. Your use of the services is at your sole risk. We do not guarantee the accuracy or timeliness of information available from the service. Copyright: NatureShare software is copyright Reilly Beacom (2014) (Australia) ...
Common areas. As is expected of such a long-established, community based facility you will feel as though you are entering a calm and welcoming home-like environment. Residents are provided with large, open lounge areas, comfortably furnished with individual recliner chairs and couches, and large TV (LCD) screens for ease of viewing, or may escape into quieter sitting rooms. Fresh, daily-made meals are served in the large open dining areas or alternatively there is a private dining room for residents and family, designed to make you feel relaxed and at home.. Sweeping gardens with uninterrupted views to the Grampians provide space to stroll and relax within private and secure outdoor areas that incorporate courtyards, established trees, manicured gardens and raised garden beds, and peaceful retreats maintained by community volunteers. All of this and yet only a short walk into the centre of town, where an array of shops and local businesses boast services for your convenience.. In addition to ...
Some of the best climbing in a Australia in a beautiful environment, often in great solitude • The Sheltered Workshop, a crag inside Grampians, Australia • Trad climbing info
Following the recent success of the smoking cessation sessions at RGU, we followed up with the two advisors from NHS Grampian who ran the sessions. As a whole the sessions were a great success. Two people followed the journey through to the quitting stage, which is really exciting, well done to them! Other people managed…
OBJECTIVE: To examine use of thrombolytic drugs for myocardial infarction and use of contraindications to treatment in the United Kingdom. DESIGN: Observational study, based on a continuing audit. SETTING: 39 hospitals in the United Kingdom. PATIENTS: 30,029 patients admitted between November 1992 and June 1995 with suspected myocardial infarction. RESULTS: Of 13,628 patients with a final diagnosis of definite myocardial infarction 10,316 (75.7%) were considered eligible for thrombolytic treatment on the basis of typical cardiographic changes or new left bundle branch block. Of these, 8139 (59.7%) were diagnosed at admission to hospital and 6991 (85.9%) were administered thrombolytic drugs; 14.1% were considered too late for treatment or had a clinical contraindication. In 2177 patients (16% of 13,628)-thrombolytic treatment was given in the absence of contraindications and after the diagnosis of infarction had been confirmed by further electrocardiographic evidence. A further 591 (4.3%) with a ...
Streptokinase (SK) is a bacterial protein used clinically as a thrombolytic agent in humans. Administration of SK causes a rapid increase in the frequency of anti-SK T cells and the titre of specific anti-SK antibodies that, on subsequent administration of SK, may neutralize the activity of the drug or elicit allergic-type reactions. By locating and modifying the immunogenic T-cell epitopes within the SK protein, it is possible that an agent with reduced immunogenicity but equal efficacy may be produced. We have investigated the T-cell epitopes within SK using nine non-overlapping, recombinant peptide fragments of SK. We investigated the proliferative T-cell response of peripheral blood mononuclear cells obtained from patients before and 6 days after administration of SK for myocardial infarction. We also examined the response of cultured anti-SK T-cell lines derived from patients 6 days after treatment with SK. Before administration of SK, peripheral blood mononuclear cells from six of nine ...
DALLAS - The use of thrombolytics before angioplasty or stenting offers no benefit and appears to increase the risk of heart attacks, strokes, or death.
Now complete, Bennetts Associates Suttie Centre aims to forge links between medical teaching and clinical practice. The £21m project is a partnership between the University of Aberdeen and NHS Grampian housing state-of-the-art teaching and learning
Do you want to stop smoking but dont know where to start? Over the coming months, in conjunction with NHS Grampian, we will be offering Smoking Cessation advice, group sessions and drop in opportunities for all students and staff on campus. Promotional material will be available in the next couple of weeks, with sessions starting in…
A new study into the treatment of gallbladder stones, which lead to around 80,000 operations a year, is being directed by NHS Grampian and the University of Aberdeen.
Thrombolytic drugs or clot-busters are used to dissolve blood clots that are blocking blood flow to the heart. When given soon after a heart attack begins, these drugs can limit or prevent permanent damage to the heart. To he most effective, these drugs need to be administered within one hour from the commencement of the attack. ...
Two special forums will be held in Ararat and Horsham. Thanks to a generous contribution from RACV, and local support from Grampians Integrated Cancer Service, these forums will be free.
By ROSALIND GRIFFITHS A MAN who had a lung removed by surgeons in Aberdeen after a mistaken cancer diagnosis is claiming compensation from NHS Grampian. Former firefighter Laurie Ball, 58, from Mossbank, was told shortly after the operation that he did not have cancer, but he said that he has had neither an
The purpose of this study was to determine the pattern of mouthwash use and to investigate the associated factors in general population.
In an unblinded trial of intravenous streptokinase (SK) in early acute myocardial infarction, 11 806 patients in one hundred and seventy-six coronary care units were enrolled over 17 months. Patients admitted within 12 h after the onset of symptoms a
Rb-Sr and 40Ar/39Ar step-heating and in situ 40Ar/39Ar laserprobe dating of fabric-forming micas provide new constraints on the timing of Grampian orogenesis and the associated development of blueschist-facies metamorphism at the Laurentian margin in NW Ireland. Early (MP1) blueschist-facies assemblages were developed in metabasites of the Dalradian Supergroup deposited near the edge of the incipient Laurentian margin, contemporaneous with Barrovian metamorphism in the Dalradian closer to the Laurentian foreland. The regional D2 event is associated with the formation of orogen-scale fold nappes and is constrained in the Dalradian by S2 muscovite ages of c. 460 Ma, which are probably recording crystallization. Importantly, the Clew Bay Complex, previously considered as an exotic terrane (correlated with the Highland Border Complex of Scotland) and the Dalradian are in structural continuity. Muscovite from the S2 nappe fabric in the Clew Bay Complex also yields identical c. 460 Ma ages. During D3, ...
THE Geelong region has just shivered through a week of icy weather with Aireys Inlet recording its coldest first 10 days of May on record. Sheep are now shorn in autumn for greater profits, argues a reader. Snow has fallen on the Grampians range
Britton Streptokinase is a medicine available in a number of countries worldwide. A list of US medications equivalent to Britton Streptokinase is available on the Drugs.com website.
Discover our complete range of sports nutrition online, including the Everlast Creatine Mono, available to order online now with next day delivery!
Objective: To examine the association between hypertensive diseases of pregnancy (gestational hypertension and pre-eclampsia) and the development of circulatory diseases in later life.. Design: Cohort study of women who had pre-eclampsia during their first singleton pregnancy. Two comparison groups were matched for age and year of delivery, one with gestational hypertension and one with no history of raised blood pressure.. Setting: Maternity services in the Grampian region of Scotland.. Participants: Women selected from the Aberdeen maternity and neonatal databank who were resident in Aberdeen and who delivered a first, live singleton from 1951 to 1970.. Main outcome measures: Current vital and cardiovascular health status ascertained through postal questionnaire survey, clinical examination, linkage to hospital discharge, and mortality data.. Results: There were significant positive associations between pre-eclampsia/eclampsia or gestational hypertension and later hypertension in all measures. ...
OBJECTIVE--To evaluate the impact of a fast track triage system for patients with acute myocardial infarction. DESIGN--Comparison of delays in admission to hospital and in receiving thrombolytic treatment before and after introducing fast track system with delays recorded in 1987-8. Patients fulfilling clinical and electrocardiographic criteria for myocardial infarction were selected for rapid access to the cardiac care team, bypassing evaluation by the medical registrar. SETTING--Major accident and emergency, cardiac and trauma centre. SUBJECTS--359 patients admitted to the cardiac care unit during 1 February to 31 July 1990 with suspected acute infarction. MAIN OUTCOME MEASURES--Accuracy of diagnosis and delay from arrival at hospital to thrombolytic treatment. RESULTS--248 of the 359 patients had myocardial infarction confirmed, of whom 127 received thrombolytic treatment. The fast track system correctly identified 79 out of 127 (62%) patients who subsequently required thrombolytic treatment. ...
Acute stroke is the third leading cause of mortality in developed countries and the major medical cause of disability in adults. The outcome can be improved by early treatment with thrombolysis. Alteplase (r-tPA) is the only approved thrombolytic drug in the indication of acute ischemic stroke. However, the use of alteplase is currently restricted by the need to administer it within 3 hours of symptom onset. As the risk of transforming a cerebral infarct into haemorrhage probably rises as the time elapsed increases, a thrombolytic drug that carries a lower risk of haemorrhage than alteplase may offer a wider time-to-treatment window and improve the safety profile ...
I first published this story back in April 2015. Recently, I spoke about this weevil on ABC Radio Ballarat and also at a talk I gave to Friends of the Grampians Gariwerd (FOGG) so I thought now is a good time to republish.. I found this fellow trundling along the road when I went for my morning walk the other day. This insect is commonly known as a Botany Bay weevil (Chrysolopus spectabilis) or by its other common name "diamond weevil". This is the male of the species. Females are larger insects, making males the lesser of two weevils (sorry, I couldnt resist!).. ...
A mother who was told she had terminal cancer arranged her funeral and wrote farewell letters to her young sons - only to be told the diagnosis was a mistake.. Denise Clark, 34, said her life was made "absolute hell" for two years after she was given the wrong prognosis at Aberdeen Royal Infirmary.. She spent £10,000 on treatment at an alternative therapy clinic in Spain in the hope of prolonging her life and went on what she thought was a last summer holiday with her family.. But after growing suspicious about how well she was feeling, Ms Clark demanded another scan - which revealed the growth in her pelvis was not malignant after all.. Now the mum of two has settled a claim for a high five-figure sum after she raised proceedings against NHS Grampian following the errors in her care.. Ms Clark, mother to Harvey, 10, and Luca, four, said she hoped no one else would suffer the heartache she had gone through.. "Hearing them say it was a mistake was amazing and there is a future now, but it ...
The APSACs recommendations focus on the diagnosis and assessment of attachment problems in children, along with treatments and interventions as well as recommendations for child welfare agencies. Regarding diagnosis and assessment, the APSAC advises that attachment problems, including but extending beyond RAD, are an appropriate concern for professionals who work with maltreated children and should be carefully considered when these children are assessed. The term "attachment disorder" is not part of any accepted system for classifying behavioral or mental disorders; however, there is a narrower and better accepted condition called "reactive attachment disorder" (RAD), which is described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). The core feature of RAD is severely inappropriate social relating that begins before age 5 years. RAD symptoms typically involve one of two extreme behaviors: indiscriminate and excessive attempts to receive comfort and affection from any ...
The early determination of whether a patient presenting with chest pain is truly having an MI has 2 important ramifications, only 1 of which is addressed by Puleo and colleagues. The authors rightly point out that resources are wasted when patients without MIs are placed in units designed to care for patients with MIs. Another important aspect of an early and accurate diagnosis of infarction is to allow for early treatment with thrombolytic drugs. This study clearly shows that CK-MB subforms detect MI within 6 hours after the onset of symptoms. It is clear that patients presenting with "big-bang" infarctions (i.e., significant ST-segment elevation) will need to receive thrombolytic drugs as early as possible and that in this group of patients an elevation of CK-MB subform would be of little value. The management of patients with a good history and equivocal electrocardiographic changes can be more difficult. Thus, although providing valuable information on the sensitivity and specificity of ...
Objective-To evaluate integrated care for diabetes in clinical, psychosocial, and economic terms. Design-Pragmatic randomised trial. Setting-Hospital diabetic clinic and three general practice groups in Grampian. Patients-274 adult diabetic patients attending a hospital clinic and registered with one of three general practices. Intervention-...
In a nutshell:​ If you take more than an idle interest in our feathered friends, privately owned Faccenda Group is your employer of choice. The second largest chicken processor in the UK after Grampian Country Food Group, Faccenda is a fully integrated agriculture and chicken processing business handling more than 2m birds a week from facilities across the UK. History:​ Established over 40 years ago by Sunday Times rich list regular Robin Faccenda and family, Faccenda has grown through a series of acquisitions including Hinton Poultry, Perry Poultry and Webbs Country Foods, and now turns over a cool £300m.. Operating from six sites in the UK, Faccenda supplies large supermarket chains and restaurants with whole chickens, breasts, chicken portions and value added products. Brands youd recognise:​ You wont. Faccenda supplies own-label products.. The strategy:​ Sticking to its knitting and keeping customers happy with high quality whole chickens and chicken portions, plus more value ...
Glossary of Terms Thrombolytic Therapy The use of medication that has the ability to dissolve blood clots in a vein or artery. ...
Find the best thrombolytic therapy doctors in Mumbai. Get guidance from medical experts to select thrombolytic therapy specialist in Mumbai from trusted hospitals - credihealth.com
The purpose of this course is to increase clinicians knowledge of thrombolytic medications so that they can identify the optimal therapy and safely use these medications.
New (4/25/16) Interim Guidance from CDC and OSHA for Protecting Workers from Occupational Exposure to Zika Virus View Here Main Zika CDC Page FirstWatch Medical Director Alex Garza on Fox 2 Now St. Louis talking Zika Virus View Here Zika, What You Should Know: FirstWatch Medical Director Alex Garza on St. Louis on the Air View Here FirstWatch Medical Director Alex Garza on Zika in on PBS SciTech Now Episode View Here 10 Questions About Zika Answered by CDC View Here History and Current Areas Effected View Here Poster for Definitions of Local Cases View Here Poster for Definitions of Imported Cases View Here Currently Known Routes of Transmission View Here MMWR: Zika in Pregnancy View Here Blood Transfusion View Here Sexual Transmission: Male to Female View Here MMWR: Zika Sexual Transmission View Here CDC Signs & Symptoms, Diagnosis, and Recommended Treatment View Here CDC: Mosquito Control View Here CDC: Zika Prevention View Here CDC: Health Care Worker - Clinical Evaluation View Here CDC: ...
Be prepared with the most accurate 10-day forecast for Macuso, Angola with highs, lows, chance of precipitation from The Weather Channel and Weather.com
The Maryland high school student who fatally shot a classmate last week and injured another died from a self-inflicted gunshot, officials said Monday.

RRH: Rural and Remote Health article: 2013 -  Thrombolysis for acute ST elevation myocardial infarction:  a pilot study...RRH: Rural and Remote Health article: 2013 - Thrombolysis for acute ST elevation myocardial infarction: a pilot study...

Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase ...
more infohttps://www.rrh.org.au/journal/article/2013

Anistreplase - DrugBankAnistreplase - DrugBank

Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen- ... Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots. ... Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the ... Anistreplase. Accession Number. DB00029 (BTD00102, BIOD00102) Type. Biotech. Groups. Approved. Biologic Classification. Protein ...
more infohttps://www.drugbank.ca/drugs/DB00029

Anistreplase - WikipediaAnistreplase - Wikipedia

Anistreplase is a thrombolytic drug. Anistreplase has been developed by Beecham as Eminase. It is also known as anisoylated ... Grampion Region Early Anistreplase Trial (GREAT)". J Epidemiol Community Health. 47 (5): 377-381. doi:10.1136/jech.47.5.377. ... "Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners". Br J Gen Pract. 45 ... new evidence from Grampian region early anistreplase trial (GREAT)". BMJ. 312 (7025): 212-5. doi:10.1136/bmj.312.7025.212. PMC ...
more infohttps://en.wikipedia.org/wiki/Anistreplase

Anisoylated plasminogen streptokinase activator complex | definition of anisoylated plasminogen streptokinase activator complex...Anisoylated plasminogen streptokinase activator complex | definition of anisoylated plasminogen streptokinase activator complex...

anistreplase. (redirected from anisoylated plasminogen streptokinase activator complex). Also found in: Acronyms. anistreplase ... anistreplase. See APSAC. anistreplase. A clot-dissolving drug used to try to re-establish blood flow in the heart muscle in the ... anistreplase. /an·is·trep·lase/ (an″is-trep´lās) a thrombolytic agent used to clear coronary vessel occlusions associated with ... anistreplase. a plasminogen activator. indication This drug is used in acute MI for lysis of coronary artery thrombi. ...
more infohttp://medical-dictionary.thefreedictionary.com/anisoylated+plasminogen+streptokinase+activator+complex

Coronary Artery Disease - RxMed.comCoronary Artery Disease - RxMed.com

Eminase (Anistreplase). EMINASE® Roberts Anistreplase Fibrinolytic Agent Action And Clinical Pharmacology: Anistreplase is an ...
more infohttps://www.rxmed.com/b.main/b1.illness/b1.1.illnesses/CORONARY_ARTERY_DISEASE.htm

Eminase Side Effects in Detail - Drugs.comEminase Side Effects in Detail - Drugs.com

... anistreplase). Includes common and rare side effects information for consumers and healthcare professionals. ... Applies to anistreplase: intravenous powder for injection. Hematologic. Hematologic side effects of anistreplase (the active ... Anistreplase antibodies may decrease the effectiveness of anistreplase when readministration occurs within 5 days to 12 months ... Note: This document contains side effect information about anistreplase. Some of the dosage forms listed on this page may not ...
more infohttps://www.drugs.com/sfx/eminase-side-effects.html

Dalteparin (Subcutaneous Route) Proper Use - Mayo ClinicDalteparin (Subcutaneous Route) Proper Use - Mayo Clinic

This medicine may increase your chance of bleeding or bruising. This risk is higher if you have poorly controlled high blood pressure, a heart infection, ulcers of the stomach, or other bleeding problems. Check with your doctor right away if you notice any unusual bleeding or bruising, black, tarry stools, blood. in the urine or stools, or pinpoint red spots on your skin. Avoid picking your nose. If you need to blow your nose, blow it gently. This medicine may increase your chance of serious bleeding or nerve problems in your spine. This risk is higher if you have a catheter in your back for pain medicine or anesthetics, or have an injection into your spine (sometimes called an "epidural" or "spinal"). Other things that increase this risk are traumatic or repeated epidural or spinal punctures in the past, spinal deformity, previous spinal surgery, or use of other medications that increase the risk of bleeding. Check with your doctor right away if you develop weakness or numbness in your legs or ...
more infohttps://www.mayoclinic.org/drugs-supplements/dalteparin-subcutaneous-route/proper-use/drg-20063314?p=1

Protein c, human Intravenous Advanced Patient Information - Drugs.comProtein c, human Intravenous Advanced Patient Information - Drugs.com

Detailed drug Information for protein c, human Intravenous. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
more infohttps://www.drugs.com/cons/protein-c-human-intravenous.html

Pentosan Polysulfate Sodium (Oral Route) Proper Use - Mayo ClinicPentosan Polysulfate Sodium (Oral Route) Proper Use - Mayo Clinic

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.. ...
more infohttps://www.mayoclinic.org/drugs-supplements/pentosan-polysulfate-sodium-oral-route/proper-use/DRG-20065410?p=1

Dabigatran Etexilate MesylateDabigatran Etexilate Mesylate

Anistreplase (major, theoretical). *Argatroban (major, theoretical). *Aspirin (major, theoretical). *. B*Bivalirudin (major, ...
more infohttps://www.medpagetoday.com/drugs/Dabigatran-Etexilate-Mesylate/929742

Safety and Effectiveness of tPA in Intra-Abdominal AbscessesSafety and Effectiveness of tPA in Intra-Abdominal Abscesses

Anistreplase. An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is ...
more infohttps://www.bioportfolio.com/resources/trial/102695/Safety-and-Effectiveness-of-tPA-in-Intra-Abdominal-Abscesses.html

Fibrin Modulating Agents - DrugBankFibrin Modulating Agents - DrugBank

Anistreplase. Plasminogen activator inhibitor 1. target. DB00031. Tenecteplase. Urokinase plasminogen activator surface ... Anistreplase. For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction. ...
more infohttps://www.drugbank.ca/categories/DBCAT000011

Patent US20060201601 - Flexible markers - Google PatentsPatent US20060201601 - Flexible markers - Google Patents

... anistreplase and/or derivatives thereof; antagonists of vascular epithelial growth factor and/or derivatives thereof; anti- ...
more infohttp://www.google.com.au/patents/US20060201601

Cardiovascular Disease: Treatment Strategies | Largo Medical Center | Largo, FLCardiovascular Disease: Treatment Strategies | Largo Medical Center | Largo, FL

Anistreplase. Other Medications. Most of the medications used to reduce the risk of CVD are also used in its treatment. These ...
more infohttps://largomedical.com/hl/?/31502/How-is-cardiovascular-disease-treated&com.dotmarketing.htmlpage.language=1

Welcome to HoPaCIWelcome to HoPaCI

2013 - Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH) Ingolstädter Landstraße 1, D-85764 Neuherberg, Germany. Disclaimer: IBIS Databases and associated information are protected by copyright. This server and its associated data and services are for academic, non-commercial use only. The Helmholtz Zentrum München has no liability for the use of results, data or information which have been provided through this server. Neither the use for commercial purposes, nor the redistribution of IBIS database files to third parties nor the distribution of parts of files or derivative products to any third parties is permitted. Commercial users shall contact the Helmholtz Zentrum München for a separate users license.. ...
more infohttp://mips.helmholtz-muenchen.de/HoPaCI/entry/show/2792?iList=25820&term=%26quot%3BexoU%26quot%3B&refFieldSingle=Gene%2FProtein%2FComplex

NREMT Paramedic Medications by Ricky OlivarezNREMT Paramedic Medications by Ricky Olivarez

Anistreplase (Apsac). 12. Aspirin (Acetylsalicylic Acid). 13. Atenolol. 14. Atracurium. 15. Atropine. 16. Bretylium. 17. ...
more infohttps://appadvice.com/app/nremt-paramedic-medications/351262599

Catalent Pharma Solutions Llc Product News and Research
     | CureHunterCatalent Pharma Solutions Llc Product News and Research | CureHunter

Anistreplase (APSAC), Cacao, Pinus ponderosa, type 6,11,16,18 human papillomavirus vaccine L1 (Gardasil), Cannabis, Candida ...
more infohttp://www.curehunter.com/public/fdaFirmSearch011014-Catalent-Pharma-Solutions-Llc.do

Valeant Pharmaceuticals International Product News and Research
     | CureHunterValeant Pharmaceuticals International Product News and Research | CureHunter

Anistreplase (APSAC), Cacao, Pinus ponderosa, type 6,11,16,18 human papillomavirus vaccine L1 (Gardasil), Cannabis, Candida ...
more infohttp://www.curehunter.com/public/fdaFirmSearch000187-Valeant-Pharmaceuticals-International.do

Berinert  - Side Effects, Uses, Dosage, Overdose, Pregnancy, Alcohol | RxWikiBerinert - Side Effects, Uses, Dosage, Overdose, Pregnancy, Alcohol | RxWiki

Berinert - Get up-to-date information on Berinert side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about Berinert
more infohttp://www.rxwiki.com/berinert

Heart failure post-myocardial infarction: a review of the issues | HeartHeart failure post-myocardial infarction: a review of the issues | Heart

Anistreplase, the thrombolytic agent used in GREAT, could be given as a single injection, which enabled domiciliary use. ... Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region early anistreplase trial (GREAT). J Am Coll ... who were seen by their general practitioner within four hours of symptom onset and were given intravenous anistreplase either ...
more infohttp://heart.bmj.com/content/91/suppl_2/ii3

Peripheral Thrombolysis Imaging: Overview, Choice of Agent and Mechanism of Action, Acute and Chronic IschemiaPeripheral Thrombolysis Imaging: Overview, Choice of Agent and Mechanism of Action, Acute and Chronic Ischemia

Anistreplase is not being used for peripheral vascular work. Several other new thrombolytic agents are under review, but only ... Anistreplase is an equimolar complex of streptokinase and para -anisoylated human Lys-plasminogen, or anisoylated plasminogen- ...
more infohttps://emedicine.medscape.com/article/422313-overview

Patente US8102176 - NMR device for detection of analytes - Google PatentesPatente US8102176 - NMR device for detection of analytes - Google Patentes

... anistreplase, streptokinase and urokinase; hormones and hormone modifiers, such as bromocriptine; abortifacients, such as ... anistreplase, streptokinase, and urokinase; dermatological agents, such as colchicine, isotretinoin, methotrexate, minoxidil, ... anistreplase, brinase, drotrecogin alfa, fibrinolysin, procein C, reteplase, saruplase, streptokinase, tenecteplase, and ... anistreplase, streptokinase and urokinase; antiemetics, such as prochlorperazine; salicylate gastrointestinal anti-inflammatory ...
more infohttp://www.google.es/patents/US8102176
  • Anistreplase has been developed by Beecham as Eminase. (wikipedia.org)
  • Hematologic side effects of anistreplase (the active ingredient contained in Eminase) should be anticipated. (drugs.com)
  • Since cardiovascular side effects may be more likely among the population of patients in whom anistreplase (the active ingredient contained in Eminase) is indicated, a causal relationship to anistreplase is not always clear. (drugs.com)
  • Anistreplase (the active ingredient contained in Eminase) is antigenic and has induced hypersensitivity reactions in 6% of patients. (drugs.com)
  • Metabolic changes associated with anistreplase (the active ingredient contained in Eminase) have included both hyper- and hypokalemia . (drugs.com)
  • A case of adult respiratory distress syndrome associated with the use of anistreplase (the active ingredient contained in Eminase) has been reported. (drugs.com)
  • The GREAT (Grampian Region Early Anistreplase Trial) directly addressed the issue of early thrombolysis by evaluating, in a randomised controlled trial, the efficacy of thrombolysis in the community compared with that administered in hospital. (elsevier.com)